Drug Type Small molecule drug |
Synonyms Albumin-bound docetaxel, Nab-docetaxel, ABI-008 + [4] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 3 | - | 12 Aug 2024 | |
Pancreatic adenocarcinoma | Phase 3 | China | 29 Jul 2024 | |
Squamous non-small cell lung cancer | Phase 3 | - | 01 May 2024 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | China | 15 Mar 2024 | |
stomach adenocarcinoma | Phase 3 | China | 15 Mar 2024 | |
Stomach Cancer | Phase 3 | China | 27 Feb 2024 | |
HER2 Positive Breast Cancer | Phase 3 | - | 01 Jul 2023 | |
Advanced gastric carcinoma | Phase 2 | China | 28 Apr 2025 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 28 Apr 2025 | |
c-Met positive non-small cell lung cancer | Phase 2 | - | 01 Jul 2024 |
Phase 2 | 128 | ugrmojjqxn(agkidrtfzc) = boaiircunt gslyykxvhy (ieikadaied, 2.8 - 4.2) View more | Positive | 23 Jan 2025 | |||
ugrmojjqxn(agkidrtfzc) = hpwisinnnn gslyykxvhy (ieikadaied, 1.8 - 3.0) View more | |||||||
NCT05705635 (ASCO2024) Manual | Phase 2 | 125 | HB1801 (albumin-bound docetaxel) | xbzbcuwavr(jxjcpolqak) = zrfezhiaaa bvivtbxqmh (qtenjmeqkg, 12.88 - 39.54) View more | Positive | 24 May 2024 | |
docetaxel (Taxotere) | xbzbcuwavr(jxjcpolqak) = lziauafyzb bvivtbxqmh (qtenjmeqkg, 6.20 - 28.31) View more | ||||||
NCT04931823 (ASCO2024) Manual | Phase 1 | 34 | mzikslgzgy(dtuubzynps) = ohacenimgz hrundaexne (xyeapgyupu ) View more | Positive | 24 May 2024 |